Immatics highlights HybridDIA research. Immatics stock falls 4.66 percent

Published on 10/08/2026 at 17:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HybridDIA drew attention October 7, 2026. Immatics stock costs EUR 6.34 versus EUR 6.65 on October 8, 2026, while its daily change is minus 4.66 percent.

Key points in brief

Immatics highlighted HybridDIA research at a Singapore conference on October 7, 2026.
Immatics stock was at EUR 6.34 in after-hours trading on October 8, 2026, down 4.66 percent from EUR 6.65.
Second-quarter 2026 revenue reached EUR 9.14 million, while the company launched a USD 150 million offering in August.

IMTX, NL0015285941, Illustration mit AI erstellt.

Immatics stock (ISIN NL0015285941) was at EUR 6.34 at Lang & Schwarz on October 8, 2026 at 5:48 p.m. CEST, down 4.66 percent from the EUR 6.65 prior close. As Simply Wall St reported on October 7, 2026, the company highlighted its HybridDIA approach at the 25th Human Proteome Organization World Congress in Singapore.

Research update meets a weaker chart

The conference presentation added a research angle while Immatics shares had fallen 14.60 percent over seven days and 21.60 percent over 30 days, according to Simply Wall St. The contrast leaves the company dependent on clinical progress and partner-supported development rather than current profitability.

Three financing and pipeline milestones

On May 12, 2026, Immatics reported first-quarter revenue of EUR 7.60 million, as listed by Zonebourse. On August 18, 2026, second-quarter revenue rose to EUR 9.14 million, while the net loss reached EUR 62.49 million, according to the same company news page.

On August 25, 2026, Immatics announced a USD 150 million underwritten offering, with 12,945,916 ordinary shares and pre-funded warrants described in Makkler. The financing strengthens liquidity for development work but also expands the share base.

What does the research update change?

The immediate financial picture remains investment-heavy: second-quarter operating cash flow was negative USD 60.46 million, while cash and cash equivalents stood at USD 232.46 million at June 30, 2026. MarketBeat listed a Moderate Buy consensus, six Buy ratings, one Hold and one Sell, with an average target of USD 20.60 on October 3, 2026, versus the USD 7.12 Nasdaq quote used for the comparison.

Next clinical date is in October

The next dated pipeline event is the European Society for Medical Oncology Congress from October 23 through October 27, 2026, where Immatics plans presentations across its PRAME franchise, according to Makkler. For investors, the key question is whether upcoming clinical data can justify the valuation while quarterly losses continue.

After-hours price reflects renewed pressure

At Lang & Schwarz, Immatics was trading at EUR 6.34 on October 8, 2026 at 5:48 p.m. CEST, or minus 4.66 percent versus the EUR 6.65 prior close at Lang & Schwarz on October 7, 2026. The primary Nasdaq quote was USD 7.12 at 11:53 a.m. ET on October 8, 2026, with a 52-week range of USD 7.02 to USD 12.41.

The further course of trading is shown by the continuously updated real-time quote of Immatics stock.